Chi Sheng Pharma & Biotech Co., Ltd. Statistics
Chi Sheng Pharma & Biotech Co., Ltd. (4111) Stock Statistics & Valuation Metrics
Total Valuation
Chi Sheng Pharma & Biotech Co., Ltd. has a market cap or net worth of TWD 1.69B. The enterprise value is TWD 1.39B.
- Market Cap
- TWD 1.69B
- Enterprise Value
- TWD 1.39B
Share Statistics
Chi Sheng Pharma & Biotech Co., Ltd. has 59,832,134 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 59,832,134
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Chi Sheng Pharma & Biotech Co., Ltd.’s return on equity (ROE) is 0.12 and return on invested capital (ROIC) is 10.42%.
- Return on Equity (ROE)
- 0.12
- Return on Assets (ROA)
- 0.08
- Return on Invested Capital (ROIC)
- 10.42%
- Return on Capital Employed (ROCE)
- 0.13
- Revenue Per Employee
- 17.21M
- Profits Per Employee
- 2.05M
- Employee Count
- 80
- Asset Turnover
- 0.71
- Inventory Turnover
- 8.40
Valuation Ratios
The current PE Ratio of Chi Sheng Pharma & Biotech Co., Ltd. is 9.03. Chi Sheng Pharma & Biotech Co., Ltd.’s PEG ratio is 0.32.
- PE Ratio
- 9.03
- PS Ratio
- 1.20
- PB Ratio
- 1.21
- Price to FCF
- 7.71
- Price to Operating Cash Flow
- 5.53
- PEG Ratio
- 0.32
Income Statement
In the last 12 months, Chi Sheng Pharma & Biotech Co., Ltd. had revenue of 1.38B and earned 164.28M in profits. Earnings per share was 2.75.
- Revenue
- 1.38B
- Gross Profit
- 507.61M
- Operating Income
- 199.30M
- Pretax Income
- 206.80M
- Net Income
- 164.28M
- EBITDA
- 271.75M
- Earnings Per Share (EPS)
- 2.75
Cash Flow
In the last 12 months, operating cash flow was 307.65M and capital expenditures -86.84M, giving a free cash flow of 220.81M billion.
- Operating Cash Flow
- 307.65M
- Free Cash Flow
- 220.81M
- Free Cash Flow per Share
- 3.69
Dividends & Yields
Chi Sheng Pharma & Biotech Co., Ltd. pays an annual dividend of ―, resulting in a dividend yield of 4.61%
- Dividend Per Share
- ―
- Dividend Yield
- 4.61%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 12.97%
- Earnings Yield
- 11.11%
Stock Price Statistics
- Beta
- 0.15
- 52-Week Price Change
- -7.69%
- 50-Day Moving Average
- 28.75
- 200-Day Moving Average
- 28.58
- Relative Strength Index (RSI)
- 34.02
- Average Volume (3m)
- 64.12K
Important Dates
Chi Sheng Pharma & Biotech Co., Ltd. upcoming earnings date is Mar 17, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 06, 2026
- Next Earnings Date
- Mar 17, 2027
- Ex-Dividend Date
- ―
Financial Position
Chi Sheng Pharma & Biotech Co., Ltd. as a current ratio of 2.01, with Debt / Equity ratio of 3.53%
- Current Ratio
- 2.01
- Quick Ratio
- 1.78
- Debt to Market Cap
- 0.02
- Net Debt to EBITDA
- -1.45
- Interest Coverage Ratio
- 385.50
Taxes
In the past 12 months, Chi Sheng Pharma & Biotech Co., Ltd. has paid 42.52M in taxes.
- Income Tax
- 42.52M
- Effective Tax Rate
- 0.21
Enterprise Valuation
Chi Sheng Pharma & Biotech Co., Ltd. EV to EBITDA ratio is 4.44, with an EV/FCF ratio of 5.77.
- EV to Sales
- 0.90
- EV to EBITDA
- 4.44
- EV to Free Cash Flow
- 5.77
- EV to Operating Cash Flow
- 4.14
Balance Sheet
Chi Sheng Pharma & Biotech Co., Ltd. has TWD 472.29M in cash and marketable securities with TWD 44.98M in debt, giving a net cash position of TWD 427.30M billion.
- Cash & Marketable Securities
- TWD 472.29M
- Total Debt
- TWD 44.98M
- Net Cash
- TWD 427.30M
- Net Cash Per Share
- TWD 7.14
- Tangible Book Value Per Share
- TWD 23.40
Margins
Gross margin is 37.53%, with operating margin of 14.36%, and net profit margin of 13.31%.
- Gross Margin
- 37.53%
- Operating Margin
- 14.36%
- Pretax Margin
- 17.09%
- Net Profit Margin
- 13.31%
- EBITDA Margin
- 20.22%
- EBIT Margin
- 15.32%
Analyst Forecast
The average price target for Chi Sheng Pharma & Biotech Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 9.05%
- EPS Growth Forecast
- 36.27%
